Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more vulnerable than those in clinical trials. A retrospective review has reported data from 74 patients at three Queensland hospitals who had newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation who were...Continue Reading

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with...Continue Reading